MingMed

About MingMed

MingMed Biotechnology is a clinical-stage biopharmaceutical company founded in October 2019 by a team including Mingguo Huang, Yan Zhang, and Xuebin Liao. The Guangzhou-based firm focuses on the in-house discovery and development of first-in-class drugs to address unmet medical needs globally. The company's founders, including Chairman Huang Mingguo and CEO Zhang Yan, established the firm to translate scientific breakthroughs into clinical treatments.

MingMed operates on a business model centered on extensive research and development to build a portfolio of drug candidates, which it then advances through clinical trials. The company's revenue generation will depend on the successful commercialization of these products through regulatory approvals and potential partnerships. It has successfully raised significant capital through multiple funding rounds to finance its R&D and clinical activities, including a $60 million Series A round in March 2021 and a nearly $50 million Series A+ round in September 2021. The company filed for a Hong Kong IPO in 2022 and is reportedly planning to refile.

The company's product pipeline is diversified across four main therapeutic areas: ophthalmic drugs, recombinant botulinum toxin for medical aesthetics, immuno-oncology, and pet immune drugs. A key product is QA102, an oral small-molecule drug for treating dry age-related macular degeneration (dry-AMD), a condition with no currently approved effective treatments. Another significant candidate is YY001, a recombinant botulinum toxin type A being developed for cosmetic use, such as treating frown lines. The company has more than 10 products in its pipeline, many of which are in clinical stages in both China and the U.S.